Semaglutide vs Tirzepatide — GLP-1 vs GLP-1+GIP research
Semaglutide (Ozempic / Wegovy) is a single-receptor GLP-1 agonist. Tirzepatide (Mounjaro / Zepbound) is a dual-receptor GLP-1 + GIP agonist. Direct head-to-head trial data (SURPASS-2 and others) shows tirzepatide producing larger reductions in body weight and HbA1c at matched doses, attributable in the published mechanism literature to the additional GIP receptor arm enhancing glucose-dependent insulin secretion and direct adipose-tissue effects. Both are FDA-approved, both are once-weekly subcutaneous in published research protocols, and both are subjects of ongoing comparative research.
Side-by-side
| semaglutide-10mg | tirzepatide-30mg-kit | |
|---|---|---|
| Receptor agonism | GLP-1 | GLP-1 + GIP |
| Originator | Novo Nordisk | Eli Lilly |
| Half-life | ~7 days | ~5 days |
| Brand names | Ozempic, Wegovy, Rybelsus | Mounjaro, Zepbound |
| Trial weight loss (68-72w) | ~14.9% (STEP-1) | ~21% (SURMOUNT-1) |
| HbA1c reduction (T2D) | ~−1.6% (SUSTAIN-7) | ~−2.4% (SURPASS-2) |
| CAS number | 910463-68-2 | 2023788-19-2 |
What to know
- ·Both are GLP-1-class research compounds. The research differentiator is GIP receptor activity, present only in tirzepatide.
- ·SURPASS-2 (head-to-head, 40 weeks): tirzepatide produced larger HbA1c and weight reductions at the highest dose vs semaglutide 1mg.
- ·Side-effect profiles are similar — GI effects dominate both.
- ·Semaglutide has an oral formulation (Rybelsus); tirzepatide is subcutaneous-only.
- ·Both are research-use only on this catalogue — not sold for human or veterinary administration.
Where the literature diverges
The most cited mechanistic explanation for the magnitude difference is GIP-mediated lipolysis and adipose-tissue insulin sensitivity — tirzepatide's dual agonism appears in the literature to produce direct effects on adipocyte biology that single GLP-1 agonism does not, on top of the shared satiety / gastric-emptying effects. The phase 3 retatrutide programme (TRIUMPH) is investigating whether the further addition of glucagon agonism extends this trend.
FAQ
Is tirzepatide always better?+
Larger effects at matched doses, yes, in the trials done. Tirzepatide has a shorter clinical track record (approved 2022) than semaglutide (approved 2017), so long-term safety data is comparatively thinner. Different patient profiles and tolerability also matter — research protocols are matched to question, not dose-equivalence.
Can I use one if I stop responding to the other?+
This is a clinical question outside research-context framing. The published research literature on cross-titration and switching is limited; both are still relatively young drugs in clinical practice.
What about retatrutide?+
Retatrutide adds a third arm (glucagon) to the GLP-1+GIP combination. Phase 2 data shows larger weight-loss magnitude than tirzepatide, but it is not yet approved. See /research/retatrutide-40mg-pen for the current research summary.
This is a research-context comparison of compound mechanism and published trial outcomes. Not medical advice. Both compounds are research-use only when sold by Omega Grade — for in vitro laboratory investigation, not human or veterinary administration.
- ComparisonRetatrutide vs Tirzepatide — research differences
Retatrutide is a triple agonist (GLP-1 + GIP + glucagon); tirzepatide is a dual agonist (GLP-1 + GIP). What the research literature shows on the difference, and how it shapes what each compound is being investigated for.
- ComparisonCagrilintide vs Semaglutide — amylin vs GLP-1 research
Cagrilintide is a long-acting amylin analogue; semaglutide is a GLP-1 agonist. They target different receptor systems, and the research literature on combined CagriSema therapy is the headline story.
- ComparisonLiraglutide vs Semaglutide — daily vs weekly GLP-1 research
Liraglutide (Saxenda, Victoza) is daily; semaglutide (Ozempic, Wegovy) is weekly. The research literature shows semaglutide produces larger metabolic effects with better adherence.